Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 6, 2019. The document serves as a transaction notification regarding share allocation arrangements for Independent Non-Executive Directors for the service period of October 1, 2018, to December 31, 2018.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively details specific equity transactions involving the acquisition of notional shares.
| Instrument | Price | Total Volume Acquired |
|---|---|---|
| Ordinary Shares (GBP) | £14.95 | 4,238.959 |
| American Depositary Shares (USD) | $39.27 | 3,342.807 |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It reports routine compensation-related share acquisitions for directors.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or contingencies. It is a regulatory disclosure of director share transactions.
Key Facts for Investor Verification
- Transaction Type: Acquisition of notional shares under share allocation arrangements for Independent Non-Executive Directors.
- Service Period: Transactions relate to service rendered from October 1, 2018, to December 31, 2018.
- Participants: Transactions were executed for Sir Philip Hampton, Mr Vindi Banga, Dr Vivienne Cox, Ms Lynn Elsenhans, Dr Laurie Glimcher, Dr Jesse Goodman, Ms Judy Lewent, and Mr Urs Rohner.
- Instrument Split: Some directors received Ordinary Shares (GBP), while others received American Depositary Shares (USD).
- Valuation: The filing does not state the total monetary value of the compensation, only the unit price and volume.